Figure 2.
Figure 2. Sorafenib potently inhibits EOL-1 cells and induces apoptosis. (A) Dose-response curve illustrating the inhibition of growth of EOL-1 cells by sorafenib. Error bars show standard deviation. (B) Western blot analysis confirmed that inhibition is due to a direct effect on FIP1L1-PDGFRα. Phosphorylation of ERK1/2 was similarly decreased upon sorafenib treatment. (C) Apoptosis assay of EOL-1 and K562 cells after 24 hours of treatment with sorafenib. Treatment of EOL-1 cells with 1 nM sorafenib clearly induces apoptosis (22% apoptotic cells and 19% dead cells), whereas treatment of BCR-ABL–expressing K562 cells with 10-fold higher concentrations had no apoptotic effect.

Sorafenib potently inhibits EOL-1 cells and induces apoptosis. (A) Dose-response curve illustrating the inhibition of growth of EOL-1 cells by sorafenib. Error bars show standard deviation. (B) Western blot analysis confirmed that inhibition is due to a direct effect on FIP1L1-PDGFRα. Phosphorylation of ERK1/2 was similarly decreased upon sorafenib treatment. (C) Apoptosis assay of EOL-1 and K562 cells after 24 hours of treatment with sorafenib. Treatment of EOL-1 cells with 1 nM sorafenib clearly induces apoptosis (22% apoptotic cells and 19% dead cells), whereas treatment of BCR-ABL–expressing K562 cells with 10-fold higher concentrations had no apoptotic effect.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal